Search

Commonalities and Differences in Myeloid Malignancies: Insights from the EHA-SWG Scientific Meeting on MDS, MPN, and AML

November 2-4 - Budapest, Hungary

Meeting Chairs:

Konstanze Döhner, University Hospital Ulm, Germany
Claire Harrison, Guy's and St.

Read more

Strengthening Resilience and Fostering Collaboration: Ensuring a Transparent and Reliable Supply Chain for Plasma-Derived Products

The issue of immunoglobulin shortages and the importance of enhancing and maintaining plasma supplies have gained significant attention within the policy and regulatory landscape of the European Union.

Read more

EHA-SWG Transfusion Teaser Meeting

On March 29 the 'teaser' meeting “Transfusion medicine: a short journey around Europe” in which key opinion leaders  discussed shaping the EHA-SWG roadmap in the next 5-10 years took place virtually.

Read more

EHA leads Tutorial in Kazakhstan for better understanding of lymphomas

EHA, in collaboration with the Kazakhstan Cancer Society (KCS) and Kazakh Institute of Oncology and Radiology (KazIOR), organized its very first tutorial together on March 14-16 in Almaty, Kazakhstan.

Read more

Shining a Light on Blood Cancer

EHA Launches Digital Campaign

In September 2021, the European Hematology Association (EHA) will honor Blood Cancer Awareness Month with an extensive digital campaign.

Read more

Application forms

EHA Ranking 2024 deadline is closed. Interested in becoming an EHA sponsor? Below you will find all the application forms for all the available EHA Sponsor Programs.

Read more

About us

Welcome to the family! Get to know the YoungEHA Committee and learn how you can make a difference. Join YoungEHA through a junior membership. Meet the YoungEHA committee members:

 
 
Name: Mandy N.

Read more

‘Rare Cancers in all EU policies’: Prof Elizabeth Macintyre expresses strong EHA support for the Rare Cancers Europe agenda

On September 28, EHA President Elizabeth Macintyre addressed an audience that included Members of the European Parliament, and officials of the European Commission and the European Medicines Agency, as well as members of the Rare Cancers Europe (RCE) partnership.

Read more